GSK Plc - ADR GSK
Dividend Summary
The next GSK Plc - ADR dividend is expected to go ex in 28 days and to be paid in 3 months.
The previous GSK Plc - ADR dividend was 40.49c and it went ex 2 months ago and it was paid 7 days ago.
There are typically 4 dividends per year (excluding specials).
Latest Dividends
| Summary | Previous dividend | Next dividend |
|---|---|---|
| Status | Paid | Forecast |
| Type | Quarterly | Quarterly |
| Per share | 40.49c | Sign Up Required |
| Declaration date | 01 Feb 2024 (Thu) | – |
| Ex-div date | 22 Feb 2024 (Thu) | 16 May 2024 (Thu) |
| Pay date | 11 Apr 2024 (Thu) | 11 Jul 2024 (Thu) |
Enter the number of GSK Plc - ADR shares you hold and we'll calculate your dividend payments:
Previous Payment
$40.49
Paid on 11 Apr 2024 (Thu)
Free Email Notification
Sign up for GSK Plc - ADR and we'll email you the dividend information when they declare.
Add GSK Plc - ADR to receive free notifications when they declare their dividends.
Your account is set up to receive GSK Plc - ADR notifications.
The table below shows the full dividend history for GSK Plc - ADR
| Status | Type | Decl. date | Ex-div date | Pay date | Decl. Currency | Forecast amount | Decl. amount | Accuracy |
|---|---|---|---|---|---|---|---|---|
| Forecast | Quarterly | – | 23 Feb 2029 | 12 Apr 2029 | USD | Sign up | — | |
| Forecast | Quarterly | – | 17 Nov 2028 | 11 Jan 2029 | USD | Sign up | — | |
| Forecast | Quarterly | – | 11 Aug 2028 | 12 Oct 2028 | USD | Sign up | — | |
| Forecast | Quarterly | – | 19 May 2028 | 13 Jul 2028 | USD | Sign up | — | |
| Forecast | Quarterly | – | 25 Feb 2028 | 13 Apr 2028 | USD | Sign up | — | |
| Forecast | Quarterly | – | 19 Nov 2027 | 13 Jan 2028 | USD | Sign up | — | |
| Forecast | Quarterly | – | 13 Aug 2027 | 07 Oct 2027 | USD | Sign up | — | |
| Forecast | Quarterly | – | 21 May 2027 | 08 Jul 2027 | USD | Sign up | — | |
| Forecast | Quarterly | – | 19 Feb 2027 | 08 Apr 2027 | USD | Sign up | — | |
| Forecast | Quarterly | – | 13 Nov 2026 | 14 Jan 2027 | USD | Sign up | — | |
| Forecast | Quarterly | – | 14 Aug 2026 | 08 Oct 2026 | USD | Sign up | — | |
| Forecast | Quarterly | – | 15 May 2026 | 09 Jul 2026 | USD | Sign up | — | |
| Forecast | Quarterly | – | 20 Feb 2026 | 09 Apr 2026 | USD | Sign up | — | |
| Forecast | Quarterly | – | 14 Nov 2025 | 08 Jan 2026 | USD | Sign up | — | |
| Forecast | Quarterly | – | 15 Aug 2025 | 09 Oct 2025 | USD | Sign up | — | |
| Forecast | Quarterly | – | 16 May 2025 | 10 Jul 2025 | USD | Sign up | — | |
| Forecast | Quarterly | – | 21 Feb 2025 | 10 Apr 2025 | USD | Sign up | — | |
| Forecast | Quarterly | – | 15 Nov 2024 | 09 Jan 2025 | USD | Sign up | — | |
| Forecast | Quarterly | – | 16 Aug 2024 | 10 Oct 2024 | USD | Sign up | — | |
| Forecast | Quarterly | – | 16 May 2024 | 11 Jul 2024 | USD | Sign up | — | |
| Paid | Quarterly | 01 Feb 2024 | 22 Feb 2024 | 11 Apr 2024 | USD | 40.6c | 40.49c | 😄 |
| Paid | Quarterly | 01 Nov 2023 | 16 Nov 2023 | 11 Jan 2024 | USD | 33.99c | 35.64c | 😃 |
| Paid | Quarterly | 26 Jul 2023 | 17 Aug 2023 | 12 Oct 2023 | USD | 36.04c | 34.35c | 😃 |
| Paid | Quarterly | 26 Apr 2023 | 18 May 2023 | 13 Jul 2023 | USD | 34.71c | 36.09c | 😃 |
| Paid | Quarterly | 01 Feb 2023 | 23 Feb 2023 | 13 Apr 2023 | USD | 33.88c | 34.19c | 😄 |
| Paid | Quarterly | 02 Nov 2022 | 17 Nov 2022 | 12 Jan 2023 | USD | — | 33.48c | |
| Paid | Quarterly | 27 Jul 2022 | 18 Aug 2022 | 06 Oct 2022 | USD | — | 36.95c | |
| Paid | Quarterly | 02 May 2022 | 19 May 2022 | 01 Jul 2022 | USD | — | 34.14c | |
| Paid | Quarterly | 09 Feb 2022 | 24 Feb 2022 | 07 Apr 2022 | USD | — | 60.35c | |
| Paid | Quarterly | 28 Oct 2021 | 18 Nov 2021 | 13 Jan 2022 | USD | — | 51.68c | |
| Paid | Quarterly | 30 Jul 2021 | 19 Aug 2021 | 07 Oct 2021 | USD | — | 51.75c | |
| Paid | Quarterly | 04 May 2021 | 20 May 2021 | 08 Jul 2021 | USD | — | 52.62c | |
| Paid | Quarterly | – | 18 Feb 2021 | 08 Apr 2021 | USD | — | 63.67c | |
| Paid | Quarterly | – | 12 Nov 2020 | 14 Jan 2021 | USD | — | 51.67c | |
| Paid | Quarterly | 29 Jul 2020 | 13 Aug 2020 | 08 Oct 2020 | USD | — | 49.29c | |
| Paid | Quarterly | 29 Apr 2020 | 14 May 2020 | 09 Jul 2020 | USD | — | 47.39c | |
| Paid | Quarterly | 05 Feb 2020 | 20 Feb 2020 | 09 Apr 2020 | USD | — | 56.7c | |
| Paid | Quarterly | – | 14 Nov 2019 | 09 Jan 2020 | USD | — | 49.98c | |
| Paid | Quarterly | – | 08 Aug 2019 | 10 Oct 2019 | USD | — | 46.58c | |
| Paid | Quarterly | – | 16 May 2019 | 11 Jul 2019 | USD | — | 47.3c | |
| Paid | Quarterly | 07 Feb 2019 | 21 Feb 2019 | 11 Apr 2019 | USD | — | 60.17c | |
| Paid | Quarterly | 01 Nov 2018 | 15 Nov 2018 | 10 Jan 2019 | USD | — | 48.38c | |
| Paid | Quarterly | 25 Jul 2018 | 09 Aug 2018 | 11 Oct 2018 | USD | — | 49.56c | |
| Paid | Quarterly | – | 10 May 2018 | 12 Jul 2018 | USD | — | 50.33c | |
| Paid | Quarterly | 07 Feb 2018 | 22 Feb 2018 | 12 Apr 2018 | USD | — | 65.17c | |
| Paid | Quarterly | – | 09 Nov 2017 | 11 Jan 2018 | USD | — | 50.37c | |
| Paid | Quarterly | – | 09 Aug 2017 | 12 Oct 2017 | USD | — | 50.1c | |
| Paid | Quarterly | 26 Apr 2017 | 10 May 2017 | 13 Jul 2017 | USD | — | 49.04c | |
| Paid | Quarterly | 08 Feb 2017 | 22 Feb 2017 | 13 Apr 2017 | USD | — | 57.12c | |
| Paid | Quarterly | – | 02 Nov 2016 | 12 Jan 2017 | USD | — | 46.21c | |
| Paid | Quarterly | 27 Jul 2016 | 10 Aug 2016 | 13 Oct 2016 | USD | — | 46.65c | |
| Paid | Quarterly | 28 Apr 2016 | 11 May 2016 | 14 Jul 2016 | USD | — | 50.02c | |
| Paid | Special | 03 Feb 2016 | 17 Feb 2016 | 14 Apr 2016 | USD | — | 57.05c | |
| Paid | Quarterly | 03 Feb 2016 | 17 Feb 2016 | 14 Apr 2016 | USD | — | 65.61c | |
| Paid | Quarterly | 28 Oct 2015 | 10 Nov 2015 | 14 Jan 2016 | USD | — | 54.9c | |
| Paid | Quarterly | 29 Jul 2015 | 12 Aug 2015 | 01 Oct 2015 | USD | — | 57.69c | |
| Paid | Quarterly | 06 May 2015 | 13 May 2015 | 09 Jul 2015 | USD | — | 58.62c | |
| Paid | Quarterly | 04 Feb 2015 | 18 Feb 2015 | 09 Apr 2015 | USD | — | 69.52c | |
| Paid | Quarterly | 22 Oct 2014 | 05 Nov 2014 | 08 Jan 2015 | USD | — | 61.3c | |
| Paid | Quarterly | 23 Jul 2014 | 06 Aug 2014 | 02 Oct 2014 | USD | — | 64.82c | |
| Paid | Quarterly | 30 Apr 2014 | 14 May 2014 | 10 Jul 2014 | USD | — | 64c | |
| Paid | Quarterly | 05 Feb 2014 | 19 Feb 2014 | 10 Apr 2014 | USD | — | 74.96c | |
| Paid | Quarterly | 23 Oct 2013 | 13 Nov 2013 | 09 Jan 2014 | USD | — | 61.61c | |
| Paid | Quarterly | 24 Jul 2013 | 07 Aug 2013 | 03 Oct 2013 | USD | — | 55.32c | |
| Paid | Quarterly | 24 Apr 2013 | 08 May 2013 | 11 Jul 2013 | USD | — | 55.02c | |
| Paid | Quarterly | 06 Feb 2013 | 20 Feb 2013 | 11 Apr 2013 | USD | — | 68.95c | |
| Paid | Quarterly | 31 Oct 2012 | 14 Nov 2012 | 03 Jan 2013 | USD | — | 57.9c | |
| Paid | Quarterly | – | 08 Aug 2012 | 04 Oct 2012 | USD | — | 52.79c | |
| Paid | Quarterly | – | 09 May 2012 | 05 Jul 2012 | USD | — | 54.91c |
| Year | Amount | Change |
|---|---|---|
| 2006 | 0.0c | — |
| 2007 | 0.0c | 0% |
| 2008 | 0.0c | 0% |
| 2009 | 0.0c | 0% |
| 2010 | 0.0c | 0% |
| 2011 | 0.0c | 0% |
| 2012 | 234.55c | 100% |
| 2013 | 246.91c | 5.3% |
| 2014 | 259.64c | 5.2% |
| 2015 | 236.82c | -8.8% |
| 2016 | 200.0c | -15.5% |
| 2017 | 214.68c | 7.3% |
| 2018 | 208.44c | -2.9% |
| 2019 | 200.56c | -3.8% |
| 2020 | 212.02c | 5.7% |
| 2021 | 216.4c | 2.1% |
| 2022 | 138.76c | -35.9% |
| 2023 | 146.57c | 5.6% |
| 2024 | Sign Up Required | |
| 2025 | Sign Up Required | |
| 2026 | Sign Up Required | |
| 2027 | Sign Up Required | |
| 2028 | Sign Up Required | |
GSK Plc Optimized Dividend Chart
The chart below shows the optimized dividends for this security over a rolling 12-month period.
- Dividend Yield Today
- 3.8%
- Optimized Yield
- Sign Up Required
- 52 Week High
- 6.1% on 14 November 2023
- 52 Week Low
- 3.6% on 22 February 2024
- Next Ex-Div-Date Countdown
- Sign Up Required
About GSK Plc
GlaxoSmithKline is a very large UK based pharmaceutical company with an excellent track record of delivering increased dividends to shareholders. In recent years it has been changing its strategy and reducing it's dependence on the pure pharmaceuticals business.
- Sector
- Pharmaceuticals & Biotechnology
- Country
- United States
- Share Price
- $39.60 (yesterday's closing price)
- Shares in Issue
- 2,072 million
- Market Cap
- $82.1bn
- 1
- Market Indices
- none
- Other listings
- GSK Plc
- Home Page URL
- https://www.gsk.com/
- Investor Relations URL
- Sign Up Required
- Dividend History URL
- Sign Up Required
- Financial Calendar URL
- Sign Up Required
GSK Plc announce an increased dividend of 16p declared for Q4 2023
The GSK Board has declared a fourth interim dividend for 2023 of 16.00p per share (Q4 2022: 13.75p per share).
GSK Plc Q3 2023 dividend of 14p declared
The GSK Plc Board has declared a third interim dividend for 2023 of 14p per share (Q3 2022: 13.75p per share).
GSK plc announce a 13.75p dividend declared for the Q4 2022
The GSK plc Board has declared a fourth dividend for 2022 of 13.75p per share (Q4 2021: 28.75p1 per share retrospectively adjusted) for the Share Consolidation.
GSK Plc has declared a second dividend for 2022 of 16.25p per share
GSK Plc has declared a second dividend for 2022 of 16.25p per share, retrospectively adjusted for the Share Consolidation. The equivalent interim dividend receivable by ADR holders will be calculated based on the exchange rate on 4 October 2022. An annual fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by the Depositary. The ex-dividend date will be 18 August 2022, with a record date of 19 August 2022 and a payment date of 6 October 2022.
GlaxoSmithKline PLC declared an interim dividend of 23pence per share
The GlaxoSmithKline PLC Board has declared a fourth interim dividend for 2021 of 23pence per share (Q4 2020: 23 pence per share).
GlaxoSmithkline 2015 full year results
Summary
·
Group sales +6% CER on a reported basis and +1% CER pro-forma
-
Pharmaceuticals £14.2 billion, -7% (-1% pro-forma); Vaccines £3.7 billion, +19% (+3% pro-forma); Consumer Healthcare £6 billion, +44% (+6% pro-forma)
·
£2 billion of new product sales driven by HIV (Tivicay, Triumeq), Respiratory (Relvar/Breo, Anoro,Incruse) and Meningitis vaccines (Menveo, Bexsero)
-
Growing sales contribution: Q4 sales £682 million, (Q3: £591 million)
-
Nucala, a new biologic treatment for severe asthma, launched at the end of 2015
-
New product sales now expected to reach £6 billion target up to two years earlier (2018 vs 2020)
·
Integration and restructuring programme on schedule
-
£1 billion incremental annual cost savings delivered in 2015 for costs of £1.9 billion
-
On track to deliver £3 billion of annual cost savings by end 2017
·
2015 core EPS 75.7p, -15% CER, ahead of financial guidance
-
Reflects short-term dilution from transaction partly offset by integration and restructuring benefits
·
2015 total EPS 174.3p, +>100% CER
-
Reflects impact of transaction gains, partly offset by restructuring charges and revaluation of the contingent consideration relating to improved outlook for HIV business
·
2016 core EPS percentage growth expected to reach double digits CER
-
If FX rates held at January average levels estimated impact of +5% on 2016 Sterling core EPS growth
·
2015 ordinary dividend of 80p and special dividend of 20p confirmed
-
Special dividend to be paid alongside Q4 ordinary dividend in April 2016
-
Continue to expect 80p full year dividend for 2016 and 2017
·
New R&D portfolio of ~40 assets to drive long-term performance; multiple development milestones expected in 2016/2017
-
Up to 10 regulatory filings include Shingrix (shingles vaccine), sirukumab (RA), Benlysta SC (lupus) and ICS/LABA/LAMA (COPD)
-
Up to 10 Phase lll starts include cabotegravir (HIV), daprodustat (anaemia) and Men ABCWY vaccine
-
Up to 20 Phase ll starts in Immuno-inflammation, Oncology, Respiratory and Infectious diseases
-
Estimated R&D rate of return maintained at 13%
GlaxoSmithKline 2015 Q2 results
Summary
·
Group sales +7% CER on a reported basis and +2% CER pro-forma
-
Pharmaceuticals £3.5 billion, -6% (+2% pro-forma); Vaccines £0.8 billion, +11% (-5% pro-forma); Consumer Healthcare £1.5 billion, +51% (+6% pro-forma)
-
New Pharmaceutical and Vaccine sales of £446 million in Q2
·
Q2 core EPS of 17.3p, flat in CER terms
-
EPS reflects dilution of Novartis transaction, ongoing pricing pressure partly offset by cost reductions
-
Integration of new Consumer and Vaccine businesses on track
-
On track to deliver targeted annual cost savings of £3 billion from all restructuring programmes
·
Total Q2 EPS of 3.1p and H1 EPS of 170.7p
-
Reflects phasing of pre-tax transaction gains and accelerated restructuring charges
·
2015 earnings guidance and 2016 outlook reiterated
-
Expect 2015 core EPS to decline at a high teen percentage rate (CER)
-
2016 core EPS percentage growth expected to reach double digits (CER)
·
Q2 dividend of 19p declared
-
Continued expectation for full year dividend of 80p
·
R&D innovation with significant potential to drive long-term Group performance
-
Progress of new respiratory portfolio continues with positive FDA AdCom recommendation for Nucala and regulatory filing for approval in Japan
-
Positive CHMP decision received for Mosquirix
-
Group has ~40 NMEs (drugs and vaccines) in Phase II/III clinical development, primarily focused on HIV, Oncology, Vaccines, Cardiovascular, Immuno-inflammation and Respiratory diseases
-
New data and prospects for advanced/early-stage pipeline to be reviewed at R&D event in November
Glaxo increases its 2014 full year dividend by 2.5% and will pay out £4 billion from Novartis transaction
We start 2015 focused on priorities critical to GSK's performance this year. These include completion of the proposed major 3-part transaction with Novartis, improved commercialisation of new products and progression of our mid-stage R&D pipeline, capitalising on product supply resumption in our Consumer business and execution of our pharmaceutical restructuring programme.
Glaxo increases 2014 Q1 dividend by 6%
First quarter dividend +6% to 19p. Share buy backs of £1-2 billion targeted during 2014
Glaxo increases 2013 Q3 dividend by 6%
Summary
■
Broadly-based sales growth with Group turnover +1% CER:
-
Pharmaceuticals and Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%, impacted by decline in China sales and Vaccines phasing
-
Consumer Healthcare +4%
-
Total Group turnover ex-divestments +1%
■
Further significant pipeline approvals and filings:
-
4 approvals; US: Tivicay for HIV and FluLaval Q-IV vaccine for flu; Europe: Tafinlar for metastatic melanoma; Japan: Relvar Ellipta for asthma
-
Positive FDA Adcom recommendation for Anoro Ellipta in COPD and positive CHMP opinion for Relvar Ellipta in asthma & COPD
-
3 FDA filings: Arzerra for first-line CLL; dolutegravir-Trii for HIV; fluticasone furoate monotherapy for asthma
■
Continued delivery of operating and financial efficiencies, strong cash generation and returns to shareholders:
-
Net cash inflow from operating activities of £2.1 billion; core tax rate 23.5%
-
Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
-
Q3 dividend: 19p (+6%)
-
£1 billion of shares repurchased by the end of Q3; continue to target £1-2 billion for the year
■
Successful implementation of measures to drive strategic focus and improve growth outlook:
-
Agreement to divest Lucozade and Ribena to Suntory for £1.35 billion and Arixtra/Fraxiparine and related manufacturing site to Aspen for £700 million
■
Full year 2013 guidance reaffirmed:
-
Core EPS growth of 3-4% on sales growth of around 1% (both CER)
